Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study confirms imaging compound identifies amyloid-beta in human brain

13.03.2007
Imaging with Pittsburgh Compound B may track treatment results, not sufficient for diagnosis

A team led by Massachusetts General Hospital (MGH) investigators has confirmed that the imaging agent Pittsburgh Compound B (PiB) binds to the protein in amyloid plaques that characterize Alzheimer's disease in the human brain. Their report in the March Archives of Neurology describes the first postmortem neuropathological study of a dementia patient who had previously participated in a PET imaging study using PiB.

"This report is an essential validation of the use of PET imaging with PiB to identify amyloid-beta deposits in the brain and as a marker of disease progression that could be used to track the benefit of new treatments," says John Growdon, MD, director of the MGH Memory Disorders Unit, the paper's senior author. "It also indicates that the interpretation of PiB PET scanning needs to be done in the context of a patient's clinical symptoms and other diagnostic studies."

Alzheimer's disease is characterized by plaques within the brain of amyloid-beta protein, which is toxic to brain cells. Previous studies have shown that PiB, invented by researchers at the University of Pittsburgh School of Medicine, binds to amyloid-beta in the brains of mice and can be detected by PET scan in the brains of human patients with a diagnosis of probable Alzheimer's disease. But since a definitive Alzheimer's diagnosis can be made only on autopsy, there had been no confirmation that PiB in human brains was detecting amyloid-beta deposits.

The Archives of Neurology report describes the case of an elderly man with symptoms that could indicate several neurological disorders. He was evaluated numerous times over a period of three years, including a standard PET scan that produced results suggesting Alzheimer's disease. His eventual diagnosis was dementia with Lewy bodies, a condition that can exist along with Alzheimer's. He also enrolled in a research study involving PiB imaging, and the results of his scan showed the imaging compound had been taken up throughout the cerebral cortex, the outer layer of the brain. Three months after participating in the imaging study, the patient died at the age of 76 following a head injury, and an autopsy was performed.

The autopsy confirmed the diagnosis of dementia with Lewy bodies and had several findings characteristic of Alzheimer's disease. While some plaques that typify Alzheimer's were seen, most amyloid-beta was found in the walls of blood vessels, a condition known as cerebral amyloid angiopathy.

"The distribution of amyloid seen at autopsy matched the overall distribution seen in the PiB imaging study; levels were higher in the cerebral cortex than in other areas of the brain," says Matthew Frosch, MD, PhD, of the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND), a study co-author. "Features of Alzheimer's pathology, amyloid plaques and neurofibrillary tangles, were observed, but not at a level that would support a separate diagnosis of Alzheimer's disease."

The researchers note that, while their results confirm that uptake of PiB indicates the presence of amyloid in the brain, a positive PiB PET scan cannot be equated with a definitive Alzheimer's diagnosis. "About 15 percent of control participants in previous PiB studies, people with no cognitive impairment, had some level of PiB uptake," says Brian Bacskai, PhD, of MGH-MIND, the paper's lead author. "Some participants who probably had Alzheimer's had low uptake, and uptake levels varied for those with a diagnosis of mild cognitive impairment. Once a safe and effective drug for removing amyloid from the brain or preventing its accumulation is developed, it will be important to see how closely PiB PET scans can track those effects."

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Studies and Analyses:

nachricht Do microplastics harbour additional risks by colonization with harmful bacteria?
05.04.2018 | Leibniz-Institut für Ostseeforschung Warnemünde

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>